of the patents deal not with end products, such as pharmaceuticals, but with production processes, such as molecular selfassembly and soft lithography involving miniaturization. Such processes could help NanoTerras partners fashion products like solar cell wiring or decorative windshield patterns, using new types of molding and printing, said Whitesides, the companys chairman.Whats happening is an explosion of interest in small technology across range of fields, he said. Because the technologies are so earlystage, we concluded it was probably too early to license them to established companies.NanoTerra has not raised venture capital, Roberts said.

Kohlberg Harvards chief technology development officer. Harvard will also receive royalties from industrial applications of the intellectual property, developed over decade in the universitys Whitesides Laboratory, said Kohlberg who is also senior associate provost, managing Harvards Office of Technology Development. Such licensing arrangements are common at research universities like Harvard and the Massachusetts Institute of Technology, both in Cambridge. While the technology development office has previously licensed nanotech patents for biomedical uses, the broad portfolio covered in the deal with NanoTerra focuses on nonbiomedical applications.

of the patents deal not with end products, such as pharmaceuticals, but with production processes, such as molecular selfassembly and soft lithography involving miniaturization. Such processes could help NanoTerras partners fashion products like solar cell wiring or decorative windshield patterns, using new types of molding and printing, said Whitesides, the companys chairman.Whats happening is an explosion of interest in small technology across range of fields, he said. The timing is perfect for nanotechnology applications.

Paul manufacturing company 3M, the German materials company Merck KGaA, major Asian electronics company it would not identify, and the US Department of Defense. Carmichael Roberts longtime commercial and scientific collaborator of Whitesides who is vice chairman and cofounder of NanoTerra, said the company hopes to sign as many as to other collaboration deals with diverse group of partners.This is the first time were going after things outside of life sciences, Roberts said. Small technology has mostly been associated with electronics in the past, things like chips. The parties did not disclose other financial details of the agreement.

Because the technologies are so earlystage, we concluded it was probably too early to license them to established companies.NanoTerra has not raised venture capital, Roberts said. Kohlberg Harvards chief technology development officer. Harvard will also receive royalties from industrial applications of the intellectual property, developed over decade in the universitys Whitesides Laboratory, said Kohlberg who is also senior associate provost, managing Harvards Office of Technology Development. Such licensing arrangements are common at research universities like Harvard and the Massachusetts Institute of Technology, both in Cambridge.

Related Blogs

  • Related Blogs on medical
  • Related Blogs on nanotechnology